Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements & Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Media
Recent Posts
Entitlement Offer to raise $4.27m
Proactive Interview with Dr Chris Burns
FDA clearance of Amplia's IND for pancreatic cancer trial in US
First patient dosed in phase 2a ACCENT trial
Investor Newsletter - December 2023
Archives
April 2024
February 2024
January 2024
December 2023
November 2023
October 2023
September 2023
August 2023
July 2023
June 2023
May 2023
April 2023
February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
Categories
Company News
Media
Uncategorized
Videos
18 Aug 2022
The Front Podcast | 18 August 2022
Read More
18 Aug 2022
MEDIA RELEASE | Australian-made treatment for pancreatic cancer – clinical trial milestone
Read More
02 Aug 2022
First patient recruited into ACCENT trial
Read More
28 Jul 2022
QUARTERLY REPORT & 4C
Read More
29 Jun 2022
The science of manufacturing, at scale
Read More
23 Jun 2022
Navigating human research ethics
Read More
09 May 2022
ABC News | Bioshares
Read More
19 Apr 2022
QUARTERLY ACTIVITIES REPORT & 4C
Read More
07 Apr 2022
VIDEO | Proactive Investors Interview, Phase 2 Clinical Trial
Read More
05 Apr 2022
New investment in pancreatic cancer research
Read More
30 Mar 2022
Amplia is hiring
Read More
17 Mar 2022
Scientific rigour is in our DNA
Read More
17 Feb 2022
Improving Pancreatic Cancer Survival Rates
Read More
11 Feb 2022
WOMEN IN SCIENCE | Rhiannon Jones, Director, Operations
Read More
01 Feb 2022
VIDEO | PROACTIVE Amplia Therapeutics readies for phase two clinical trials and "watershed year" for AMP945
Read More
24 Jan 2022
Quarterly Report & 4C
Read More
02 Dec 2021
$2.1M R&D Cash Flow Loan
Read More
30 Nov 2021
VIDEO | SMALL CAPS Amplia Therapeutics makes headway in anti-cancer clinical trial
Read More
18 Nov 2021
VIDEO | PROACTIVE Amplia Therapeutics details summary results from its phase 1 clinical trial of AMP945
Read More
17 Nov 2021
New Phase 1 Clinical Trial Data
Read More
1
2
3
4
5